Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568318 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 1,533
- Enrollment target
- 20
- Study locations
NCT03568318: Active Phase 3 study of Atopic Dermatitis, sponsored by AbbVie.
NCT03568318 is a Phase 3 study of Atopic Dermatitis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,533 participants, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03568318, a Phase 3 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,533 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Primary Outcome
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scrat
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib
- DRUG Topical corticosteroids (TCS)
Study Locations (20)
California
- Bakersfield Derma & Skin Cance /ID# 200892 - Bakersfield
- Mosaic Dermatology /ID# 200553 - Beverly Hills
- University of California Irvine /ID# 200902 - Irvine
- Therapeutics Clinical Research /ID# 200593 - San Diego
- Stanford University /ID# 200597 - Stanford
Alabama
- Total Skin and Beauty Derm Ctr /ID# 200548 - Birmingham
- Clinical Research Center AL /ID# 201865 - Birmingham
- ACCEL Research Sites /ID# 213364 - Birmingham
- Advanced Dermatology and Skin Care Centre /ID# 213550 - Mobile
Arizona
- Alliance Dermatology and MOHs Center, PC /ID#200540 - Phoenix
- Arizona Research Center, Inc. /ID# 200546 - Phoenix
- Clear Dermatology & Aesthetics Center /ID# 201257 - Scottsdale
- University of Arizona /ID# 201059 - Tucson
Colorado
- Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822 - Aurora
- Colorado Center for Dermatology, PLLC /ID# 203626 - Centennial
- Duplicate_Western States Clinical Research, Inc. /ID# 201702 - Wheat Ridge
Florida
- Clearlyderm Dermatology /ID# 207709 - Boca Raton
- Skin Care Research, LLC /ID# 200812 - Boca Raton
- Clinical Research of West Florida, Inc /ID# 203643 - Clearwater
Connecticut
- Dermatology Physicians of Connecticut /ID# 201004 - Shelton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,533 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2030-10-23 |
| Phase | Phase 3 |
What the registry record for NCT03568318 still lists
NCT03568318 is an interventional study that assigns participants to a tested intervention. Its 1,533 participants enrollment target places it among the larger protocols in the corpus, above the 599-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (156% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03568318 names 20 study sites across 6 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03568318 about?
NCT03568318 is a clinical study titled "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis". The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT03568318?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,533 participants. The study started on 2018-08-09. Estimated completion is 2030-10-23.
What conditions does trial NCT03568318 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT03568318?
The interventions under investigation include: Placebo (DRUG), Upadacitinib (DRUG), Topical corticosteroids (TCS) (DRUG).
Who is sponsoring clinical trial NCT03568318?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03568318 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03568318's enrollment target sits among peer trials
1,533 9th of 150 higher than 142 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- NCT07114510 · 1,530 participants · NA
Optimal Ventilation for Cardiac Arrest
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI